company background image

SomaLogic NasdaqGM:SLGC Stock Report

Last Price


Market Cap







12 Aug, 2022


Company Financials +
SLGC fundamental analysis
Snowflake Score
Future Growth2/6
Past Performance0/6
Financial Health6/6

SLGC Stock Overview

SomaLogic, Inc. operates as a protein biomarker discovery and clinical diagnostics company in the United States.

SomaLogic Competitors

Price History & Performance

Summary of all time highs, changes and price drops for SomaLogic
Historical stock prices
Current Share PriceUS$4.43
52 Week HighUS$14.72
52 Week LowUS$3.92
1 Month Change-9.96%
3 Month Change-18.27%
1 Year Change-61.17%
3 Year Changen/a
5 Year Changen/a
Change since IPOn/a

Recent News & Updates

Jul 26

SomaLogic acquires Palamedrix to develop next-generation SomaScan Assay

SomaLogic (NASDAQ:SLGC) to acquire Palamedrix, an innovator in DNA nanotechnology, that provides deep scientific and engineering expertise, miniaturization technology and enhanced ease-of-use capabilities that company intends to leverage as it develops the next generation of the SomaScan Assay. Under the terms of the merger agreement, company will pay at closing $35M, comprising $14M in cash and $21M in company stock. Up to an additional $17.5M may be paid in connection with the achievement of certain future revenue-based milestones.  Transaction expected to close in Q3 and is not expected to contribute to revenue. As part of the transaction, company will obtain the intellectual property covering Palamedrix’s core DNA-based technology platform for the integration of molecular biosensors onto chips.

Shareholder Returns

SLGCUS Life SciencesUS Market

Return vs Industry: SLGC underperformed the US Life Sciences industry which returned -20.2% over the past year.

Return vs Market: SLGC underperformed the US Market which returned -11.7% over the past year.

Price Volatility

Is SLGC's price volatile compared to industry and market?
SLGC volatility
SLGC Average Weekly Movement10.8%
Life Sciences Industry Average Movement11.0%
Market Average Movement7.7%
10% most volatile stocks in US Market16.9%
10% least volatile stocks in US Market3.2%

Stable Share Price: SLGC is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 11% a week.

Volatility Over Time: SLGC's weekly volatility (11%) has been stable over the past year.

About the Company

1999320Roy Smythe

SomaLogic, Inc. operates as a protein biomarker discovery and clinical diagnostics company in the United States. It develops slow off-rate modified aptamers (SOMAmers), which are modified nucleic acid-based protein binding reagents that are specific for their cognate protein; and offers proprietary SomaScan services, which provide multiplex protein detection and quantification of protein levels in complex biological samples. The company’s SOMAmers/SomaScan technology enables researchers to analyze various types of biological samples for protein biomarker signatures, which can be utilized in drug discovery and development.

SomaLogic Fundamentals Summary

How do SomaLogic's earnings and revenue compare to its market cap?
SLGC fundamental statistics
Market CapUS$807.55m
Earnings (TTM)-US$82.04m
Revenue (TTM)US$85.75m


P/S Ratio


P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
SLGC income statement (TTM)
Cost of RevenueUS$81.59m
Gross ProfitUS$4.16m
Other ExpensesUS$86.20m

Last Reported Earnings

Mar 31, 2022

Next Earnings Date

Aug 15, 2022

Earnings per share (EPS)-0.45
Gross Margin4.85%
Net Profit Margin-95.68%
Debt/Equity Ratio0%

How did SLGC perform over the long term?

See historical performance and comparison
We’ve recently updated our valuation analysis.


Is SLGC undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score


Valuation Score 2/6

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for SLGC?

Other financial metrics that can be useful for relative valuation.

SLGC key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue1.9x
Enterprise Value/EBITDA-1.8x
PEG Ration/a

Price to Sales Ratio vs Peers

How does SLGC's PS Ratio compare to its peers?

SLGC PS Ratio vs Peers
The above table shows the PS ratio for SLGC vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPSEstimated GrowthMarket Cap
Peer Average14.3x
NSTG NanoString Technologies
BNGO Bionano Genomics
NEO NeoGenomics
QTRX Quanterix
SLGC SomaLogic

Price-To-Sales vs Peers: SLGC is good value based on its Price-To-Sales Ratio (9.4x) compared to the peer average (14.3x).

Price to Earnings Ratio vs Industry

How does SLGC's PE Ratio compare vs other companies in the US Life Sciences Industry?

Price-To-Sales vs Industry: SLGC is expensive based on its Price-To-Sales Ratio (9.4x) compared to the US Life Sciences industry average (5x)

Price to Sales Ratio vs Fair Ratio

What is SLGC's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

SLGC PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio9.4x
Fair PS Ratio4.3x

Price-To-Sales vs Fair Ratio: SLGC is expensive based on its Price-To-Sales Ratio (9.4x) compared to the estimated Fair Price-To-Sales Ratio (4.3x).

Share Price vs Fair Value

What is the Fair Price of SLGC when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate SLGC's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate SLGC's fair value for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.

Discover undervalued companies

Future Growth

How is SomaLogic forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?

Future Growth Score


Future Growth Score 2/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings vs Savings Rate: SLGC is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: SLGC is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: SLGC is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: SLGC's revenue (27.5% per year) is forecast to grow faster than the US market (7.9% per year).

High Growth Revenue: SLGC's revenue (27.5% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if SLGC's Return on Equity is forecast to be high in 3 years time

Discover growth companies

Past Performance

How has SomaLogic performed over the past 5 years?

Past Performance Score


Past Performance Score 0/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


Last years earnings growth

Earnings and Revenue History

Quality Earnings: SLGC is currently unprofitable.

Growing Profit Margin: SLGC is currently unprofitable.

Past Earnings Growth Analysis

Earnings Trend: Insufficient data to determine if SLGC's year-on-year earnings growth rate was positive over the past 5 years.

Accelerating Growth: Unable to compare SLGC's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: SLGC is unprofitable, making it difficult to compare its past year earnings growth to the Life Sciences industry (15.3%).

Return on Equity

High ROE: SLGC has a negative Return on Equity (-13.29%), as it is currently unprofitable.

Discover strong past performing companies

Financial Health

How is SomaLogic's financial position?

Financial Health Score


Financial Health Score 6/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Stable Cash Runway

  • Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: SLGC's short term assets ($689.6M) exceed its short term liabilities ($27.7M).

Long Term Liabilities: SLGC's short term assets ($689.6M) exceed its long term liabilities ($68.2M).

Debt to Equity History and Analysis

Debt Level: SLGC is debt free.

Reducing Debt: SLGC had no debt 5 years ago.

Balance Sheet

Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: SLGC has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: SLGC has sufficient cash runway for more than 3 years if free cash flow continues to grow at historical rates of 8.4% each year

Discover healthy companies


What is SomaLogic current dividend yield, its reliability and sustainability?

Dividend Score


Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Cash Flow Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate SLGC's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate SLGC's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.

Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if SLGC's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if SLGC's dividend payments have been increasing.

Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.

Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as SLGC has not reported any payouts.

Discover strong dividend paying companies


How experienced are the management team and are they aligned to shareholders interests?


Average management tenure


Roy Smythe (60 yo)





Dr. Roy Smythe, MD has been Chief Executive Officer of SomaLogic, Inc since joining in November 2018 and its Director since July 2021. During the course of his career, Dr. Smythe has been an internationall...

CEO Compensation Analysis

Compensation vs Market: Roy's total compensation ($USD14.31M) is above average for companies of similar size in the US market ($USD3.92M).

Compensation vs Earnings: Roy's compensation has increased whilst the company is unprofitable.

Leadership Team

Experienced Management: SLGC's management team is considered experienced (2.6 years average tenure).

Board Members

Experienced Board: SLGC's board of directors are not considered experienced ( 2.6 years average tenure), which suggests a new board.


Who are the major shareholders and have insiders been buying or selling?

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Insufficient data to determine if shareholders have been diluted in the past year.

Top Shareholders

Company Information

SomaLogic, Inc.'s employee growth, exchange listings and data sources

Key Information

  • Name: SomaLogic, Inc.
  • Ticker: SLGC
  • Exchange: NasdaqGM
  • Founded: 1999
  • Industry: Life Sciences Tools and Services
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: US$807.548m
  • Shares outstanding: 182.29m
  • Website:

Number of Employees


  • SomaLogic, Inc.
  • 2945 Wilderness Place
  • Boulder
  • Colorado
  • 80301
  • United States


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/08/12 00:00
End of Day Share Price2022/08/12 00:00
Annual Earnings2021/12/31

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.